MedTrace Logo

Measurement of Lipogenic Flux by Deuterium Resolved Mass Spectrometry Via Non-invasive Breath Analysis

NCT05274334 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2022-11-04

No results posted yet for this study

Summary

This proof of concept- study is to measure de novo lipogenesis (DNL) non-invasively in exhaled breath in overnight-fasted humans by triggering feeding response by deuterium resolved mass spectrometry.

Conditions

  • De Novo Lipogenesis (DNL)

Interventions

OTHER

Assessment of de novo lipogenesis non-invasively in exhaled breath

1. Healthy participants have a good nights sleep whereas they don't eat during the night and until measurements. 2. They come to the lab and make first baseline exhalation sets. An exhalation set consists of 6 exhalations in Mass Spectrometer positive mode and the same in negative mode. One exhalation set takes around 7minutes from start to finish. 3. Participants consume a single oral dose of dose of 70% 2H2O at 2 g/kg body-water. 4. Participants execute several exhalation sets over time. 5. Participants consume 300g of 'Excellence Joghurt Nature gezuckert. 6. Participants execute several exhalation sets over time. 7. After around 4.5hours with regular exhalation sets taking place, the trial is concluded.

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • Fondation Botnar

    collaborator UNKNOWN

  • University Children's Hospital Basel

    lead OTHER

Principal Investigators

  • Pablo Sinues, Prof. Dr. · Universitäts-Kinderspital beider Basel (UKBB)

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-11
Primary Completion
2022-09-30
Completion
2022-09-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05274334 on ClinicalTrials.gov